Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Sonova/Phonak hearing-aid spatial-configurations study

Also known as: Hearing Aid Performance Study for Different Spatial Configurations, Beamformer Benefit, Speech Enhancer benefit, SRF-386, NCT05284903

Sonova AG

Primary source

Company

Sonova AG

Program Type

Software/Neurotech

Modality

Hearing Aid/Software

Stage

Interventional/NA

Status

Completed

Target Gene

—

Route / Mode

External hearing aid fitting/software configuration

Confidence

80%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Germany

Population

adult, hearing-aid-user, speech-in-noise, post-lingual

Trial IDs

Mechanism

Completed Sonova AG clinical investigation of Phonak hearing-aid beamformer, Speech Enhancer, and amplification-feature performance across different speech/noise spatial configurations; this is a study-level record rather than separate product programs for each feature/outcome.

Indications

Hearing Loss

Notes

Verified as a real Sonova AG-sponsored completed ClinicalTrials.gov study of Phonak hearing-aid features, not separate standalone product/program records for Beamformer Benefit, Speech Enhancer, or hearing-aid-benefit outcome labels. The registry describes a CE-marked investigational device used within intended population/use, actual enrollment of 44, completion on 2022-07-05, and no posted results in this pass. Sonova's brand page corroborates Phonak as a Sonova hearing-instruments brand.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT05284903, SRF-386, Sonova AG, Phonak, Speech Enhancer, Beamformer

Open

company

Supports: company, allCompanies, notes

IDs: Sonova, Phonak

Open

Key Events

2022-03-17